GlassScriptPhysician profile
Tri Nguyen
NPI 1255379442
$11,501.48
in general payments reported to CMS, 2019-2025
28 companies · $951 in 2025
The $951 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,103 · 2020: $1,418 · 2021: $1,474 · 2022: $1,423 · 2023: $2,262 · 2024: $1,872 · 2025: $951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,084.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,914.51 | 2021-2025 | Micra, Resolute Onyx, Azure Xt Dr Mri Surescan |
| Abbott Laboratories | $2,028.30 | 2019-2025 | Cardiomems, Jot Dx, Mitraclip |
| Medtronic Vascular, INC. | $1,608.37 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $671.26 | 2021-2025 | |
| Edwards Lifesciences Corporation | $597.71 | 2019-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boston Scientific Corporation | $573.23 | 2020-2025 | Avvigo Guidance System, Rotapro |
| Abiomed | $541.93 | 2021-2023 | Impella |
| Artivion, INC. | $459.44 | 2019-2022 | |
| Amgen INC. | $413.79 | 2019-2025 | Repatha, Repatha |
| Arbor Pharmaceuticals, INC. | $256.94 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $248.03 | 2021-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $210.94 | 2019-2023 | Farxiga |
| Regeneron Healthcare Solutions, INC. | $184.84 | 2019 | |
| Janssen Pharmaceuticals, INC | $138.21 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $116.32 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $107.77 | 2023-2025 | Ozempic, Wegovy |
| Pfizer INC. | $88.73 | 2019-2024 | |
| Philips North America LLC | $56.91 | 2022-2023 | |
| Kestra Medical Technology Services, INC. | $44.78 | 2023-2025 | Assure Wcd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.03 | 2023-2024 | Jardiance |
| Impulse Dynamics (USA) INC. | $33.16 | 2023 | Optimizer |
| Kiniksa Pharmaceuticals, LTD. | $32.60 | 2023 | Arcalyst |
| Angiodynamics, INC. | $31.21 | 2024 | Auryon Laser System 100-120 Vac |
| Sanofi-Aventis U.S. LLC | $30.10 | 2019-2020 | |
| Biosense Webster, INC. | $25.55 | 2024 | Carto 3 |
| Glaxosmithkline, LLC. | $17.66 | 2023 | Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $15.43 | 2025 | Mounjaro, Zepbound |
| Chiesi USA, INC. | $11.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tri Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.